The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...

In a stock market currently obsessed with interest rate cuts and the artificial intelligence (AI) boom, it is easy to ...

A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual ...

Across all industries, the total number of companies on track to go public could make this week the most active for IPOs ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

Stay updated on biotech layoffs in 2026! Each week, we track and analyze industry layoffs, their causes, and their impact.

Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. | Immunology biotech ...

Venture capitalists point to a surge in M&A and a glint of revival in the IPO arena as signs of better days ahead.

A life sciences hub in Syracuse is getting a major upgrade as New York pushes to grow its biotechnology sector. Gov. Kathy ...

The U.S. biotechnology market enters 2026 as the largest global biotech market, with an estimated size of $552.39 billion in 2023, and is projected to grow to $1.24 trillion by 2030.

Hands-on biotech training delivers credentials, research projects, and real lab access for San Antonio students—fueling ...